Immunovant, Inc. director Robert Graham Susman sold 2,502 shares of common stock at an average price of $27.17. The transaction was conducted under a pre-arranged 10b5-1 trading plan, leaving him with 36,394 shares.
Immunovant Director Sells Shares Under 10b5-1 Plan
IMVTinsider trading10b5-1 planbiotechnology



